GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BerGenBio ASA (OSL:BGBIO) » Definitions » Loans Receivable

BerGenBio ASA (OSL:BGBIO) Loans Receivable : kr0.00 Mil (As of Mar. 2024)


View and export this data going back to 2017. Start your Free Trial

What is BerGenBio ASA Loans Receivable?

BerGenBio ASA's Loans Receivable for the quarter that ended in Mar. 2024 was kr0.00 Mil.


BerGenBio ASA Loans Receivable Historical Data

The historical data trend for BerGenBio ASA's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BerGenBio ASA Loans Receivable Chart

BerGenBio ASA Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Loans Receivable
Get a 7-Day Free Trial Premium Member Only - - - - -

BerGenBio ASA Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

BerGenBio ASA Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.


BerGenBio ASA Loans Receivable Related Terms

Thank you for viewing the detailed overview of BerGenBio ASA's Loans Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


BerGenBio ASA (OSL:BGBIO) Business Description

Traded in Other Exchanges
Address
Mollendalsbakken 9, Bergen, NOR, 5009
BerGenBio ASA is a clinical stage oncology biotech company, which is engaged in developing therapeutics against novel drug targets that drive aggressive cancers. Its drug candidate bemcentinib (BGB324) is d is curently being developed in STK11 mutated NSCLC and severe respiratory infections including COVID-19. .

BerGenBio ASA (OSL:BGBIO) Headlines

No Headlines